Article citationsMore >>

Betteridge Z., Tansley S., Shaddick G., Chinoy H., Cooper RG., New RP., Lilleker JB., Vencovsky J., Chazarain L., Danko K., Nagy-Vincze M., Bodoki L., Dastmalchi M., Ekholm L., Lundberg IE., McHugh N; (2019) UKMyonet contributors. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019.

has been cited by the following article:

Article

Clinical Presentation and Successful Treatment of a Patient with Anti-SUMO-activating Enzyme Subunit 1 (SAE1) Dermatomyositis

1University of Florida, Department of Internal Medicine1, Gainesville, FL


American Journal of Medical Case Reports. 2023, Vol. 11 No. 11, 167-168
DOI: 10.12691/ajmcr-11-11-1
Copyright © 2023 Science and Education Publishing

Cite this paper:
Adrian M. Alonso, Matilda L. Culp. Clinical Presentation and Successful Treatment of a Patient with Anti-SUMO-activating Enzyme Subunit 1 (SAE1) Dermatomyositis. American Journal of Medical Case Reports. 2023; 11(11):167-168. doi: 10.12691/ajmcr-11-11-1.

Correspondence to: Adrian  M. Alonso, University of Florida, Department of Internal Medicine1, Gainesville, FL. Email: Adrian.alonso@medicine.ufl.edu

Abstract

Anti-SAE1 antibody is a rarely reported, myositis-specific antibody, which is most clinically associated with affecting the gastrointestinal tract, skin, and lungs. This case demonstrates a patient presenting to the hospital with signs of dermatomyositis, later found to be anti-SAE1 positive. He was promptly treated with immunosuppressive medications, including IVIG, a novel therapeutic agent for dermatomyositis. This case further elucidates the importance of identifying anti-SAE1-positive patients in dermatomyositis.

Keywords